Type I interferon (IFN-alpha/beta) rescues B-lymphocytes from apoptosis via PI3Kdelta/Akt, Rho-A, NFkappaB and Bcl-2/Bcl(XL)

Cell Immunol. 2010;263(1):31-40. doi: 10.1016/j.cellimm.2010.02.012. Epub 2010 Feb 24.

Abstract

Although IFN-alpha was reported to promote the survival of peripheral B-lymphocytes via the PI3-kinase-Akt pathway, the triggered signalling pathways involved in the protection of B cell from apoptosis need to be clarified. Using flow cytometry and western blot analysis, we have found that type 1 IFNs (IFN-alpha/beta) protect human B cells in culture from spontaneous apoptosis and from apoptosis mediated by anti-CD95 agonist, in a dose- and time-dependant manner. IFN-alpha/beta-mediated anti-apoptotic effect on human B cells was totally abrogated by blockade of IFNR1 chain. Our data indicate that PI3Kdelta, Rho-A, NFkappaB and Bcl-2/Bcl(XL) are active downstream of IFN receptors and are the major effectors of IFN-alpha/beta-rescued B cells from apoptosis. Furthermore, immunohistochemical results show marked reduction in numbers of CD20 positive B cell in both spleen and Peyer's patches from mice treated with anti-IFNR1 blocking antibody compared with control group. Moreover, ultrastructural observations of these organs show an obvious increase in apoptotic cells from mice treated with anti-IFNR1 blocking antibody. Our results provide more details about the triggered signalling pathways and the phosphorylation cascade which are involved in the protection of B cell from apoptosis after treatment with IFN-alpha/beta.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives
  • Adenine / pharmacology
  • Amides / pharmacology
  • Animals
  • Antibodies, Blocking / pharmacology
  • Apoptosis / drug effects*
  • Apoptosis / immunology
  • B-Lymphocytes / drug effects*
  • B-Lymphocytes / immunology
  • B-Lymphocytes / metabolism
  • B-Lymphocytes / pathology
  • Cells, Cultured
  • Class I Phosphatidylinositol 3-Kinases
  • Gene Expression Regulation
  • Humans
  • Imidazoles / pharmacology
  • Immunologic Memory
  • Interferon Type I / administration & dosage
  • Interferon Type I / pharmacology*
  • Lymphocyte Subsets / drug effects*
  • Lymphocyte Subsets / immunology
  • Lymphocyte Subsets / metabolism
  • Lymphocyte Subsets / pathology
  • Mice
  • NF-kappa B / antagonists & inhibitors
  • Oncogene Protein v-akt / antagonists & inhibitors
  • Peptides / pharmacology
  • Phosphoinositide-3 Kinase Inhibitors
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • Pyridines / pharmacology
  • Quinazolines / pharmacology
  • Receptors, Interferon / immunology
  • Recombinant Proteins
  • Signal Transduction / drug effects*
  • Signal Transduction / immunology
  • bcl-X Protein / metabolism
  • rho-Associated Kinases / antagonists & inhibitors

Substances

  • Amides
  • Antibodies, Blocking
  • IC 87114
  • Imidazoles
  • Interferon Type I
  • NF-kappa B
  • Peptides
  • Phosphoinositide-3 Kinase Inhibitors
  • Proto-Oncogene Proteins c-bcl-2
  • Pyridines
  • Quinazolines
  • Receptors, Interferon
  • Recombinant Proteins
  • SN50 peptide
  • bcl-X Protein
  • Y 27632
  • Class I Phosphatidylinositol 3-Kinases
  • Pik3cd protein, mouse
  • Oncogene Protein v-akt
  • rho-Associated Kinases
  • Adenine
  • SB 203580